Primary prevention of type 2 diabetes: Lifestyle intervention works and saves money, but what should be done with smokers?

Annals of Internal Medicine

Volumn 142, Issue 5, 2005, Pages 381-383

  Tuomilehto, Jaakko ^a,b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b SOUTH OSTROBOTHNIA CENTRAL HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METFORMIN;

CANCER; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIETARY INTAKE; DISEASE COURSE; GLUCOSE TOLERANCE; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; WEIGHT GAIN;

EID: 14344253415     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-142-5-200503010-00013     Document Type: Review

References (21)

1. Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J (Clin Res Ed). 1981;282:1847-51.
2. Epstein FH, Holland WW. Prevention of chronic diseases in the community - one-disease versus multiple-disease strategies. Int J Epidemiol. 1983;12:135-7.
3. Epstein FH, Francis T Jr, Hayner NS, Johnson BC, Kjelsberg MO, Napier JA, et al. Prevalence of chronic diseases and distribution of selected physiologic variables in a total community, Tecumseh, Michigan. Am J Epidemiol. 1965;681:307-22.
4. Abramson JH, Gofin J, Peritz E, Hopp C, Epstein LM. Clustering of chronic disorders - a community study of coprevalence in Jerusalem. J Chronic Dis. 1982;35:221-30.
5. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137:149-55.
6. Tuomilehto J. Primary prevention of non-communicable diseases. In: Hitman GA, ed. Type 2 Diabetes: Prediction and Prevention. Chichester, United Kingdom: J Wiley; 1999:211-38.
7. Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin- dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia. 1991;34:891-8.
8. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-44.
9. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-50.
10. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
11. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-7.
12. Knowler WC, Narayan KM, Hanson RL, Nelson RG, Bennett PH, Tuomilehto J, et al. Preventing non-insulin-dependent diabetes. Diabetes. 1995;44:483-8.
13. Davey Smith G, Bracha Y, Svendsen KH, Neaton JD, Haffner SM, Kuller LH. Incidence of type 2 diabetes in the randomized Multiple Risk Factor Intervention Trial. Ann Intern Med. 2005;142:313-22.
14. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA. 1982;248:1465-77.
15. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002;136:575-81.
16. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26:725-31.
17. Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ. 1995;310:555-9.
18. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens. 2002;20:2099-110.
19. Marti B, Tuomilehto J, Salomaa V, Kartovaara L, Korhonen HJ, Pietinen P. Body fat distribution in the Finnish population: environmental determinants and predictive power for cardiovascular risk factor levels. J Epidemiol Community Health. 1991;45:131-7.
20. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323-32.
21. Finnish Diabetes Association. Development Programme for the Prevention and Care of Diabetes in Finland 2000-2010. Tampere, Finland: Finnish Diabetes Association; 2001.